Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | March 28, 2024 | March 29, 2024 |
| Medtronic plcMDT · Entity 2888 | Director | April 27, 2026 | April 29, 2026 |
| MiniMed Group, Inc.MMED · Entity 3758 | Director | October 09, 2026 | October 13, 2026 |
| NEW RITE AID, LLCRAD · Entity 87704 | Director | July 07, 2021 | July 09, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date March 28, 2024 · Filed March 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,258.1388 |
Reported balance
After 2024-03-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-03-28 · Grant · Acquired 33.8931 · Balance 3,258.1388 F1: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate. F3: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of phantom stock is the economic equivalent of one share of Gilead common stock.
F2: Phantom shares accrued under dividend equivalent rights, which are settled in shares and distributed with the phantom stock units to which they relate.
F3: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person.
Medtronic plc
Report date April 27, 2026 · Filed April 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,347 |
Reported balance
After 2026-04-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-27 · Grant · Acquired 2,111 · Balance 10,347 F1: Represents an award of restricted stock units that vest on the one-year anniversary of the award date. F2: Includes 65 shares acquired through dividend reinvestment since the last report filed by the reporting person. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,140 |
Reported balance
After 2026-04-28 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-04-28 · Tax withholding · Disposed 207 · Balance 10,140 F3: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units that vest on the one-year anniversary of the award date.
F2: Includes 65 shares acquired through dividend reinvestment since the last report filed by the reporting person.
F3: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I.
MiniMed Group, Inc.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,573 |
Reported balance
After 2026-10-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-09 · Grant · Acquired 11,795 · Balance 39,573 F1: Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest on the one-year anniversary of the grant date. F2: Includes shares of common stock to be issued in connection with the vesting of one or more RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest on the one-year anniversary of the grant date.
F2: Includes shares of common stock to be issued in connection with the vesting of one or more RSUs.
NEW RITE AID, LLC
Report date July 07, 2021 · Filed July 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,943 |
Reported balance
After 2021-07-07 transaction · row 1
1 source rowRow 1 · 2021-07-07 · Grant · Acquired 10,617 · Balance 45,943 F1: Grant of restricted stock exempt from Section 16(b) under Rule 16b-(3)(d). |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 250 |
Reported balance
Holding disclosure · report date 2021-07-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 250 |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock exempt from Section 16(b) under Rule 16b-(3)(d).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2014 Filed May 9, 2014 00:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (Right to Buy) · Derivative | 4,868 | $0.00 Strike: $78.77 | $0.00 |
DisclosureSEC source: 0001179110-14-008006 · edgar.xml · derivative · entry 4 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,868 Underlying: Common Stock · 4,868 shares Expires 2024-05-07 F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 7, 2015, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 07, 2014 Filed May 9, 2014 00:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 1,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-14-008006 · edgar.xml · derivative · entry 3 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,904 Underlying: Common Stock · 1,904 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 7, 2015, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 7, 2015, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 06, 2014 Filed May 9, 2014 00:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 2,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-14-008006 · edgar.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,863 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F4 · derivative.exercise_date: 100% of the restricted stock units vested on May 6, 2014. F4 · derivative.expiration_date: 100% of the restricted stock units vested on May 6, 2014. Read SEC document |
| May 06, 2014 Filed May 9, 2014 00:41 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-14-008006 · edgar.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| July 01, 2013 Filed Jul 3, 2013 21:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 1,669 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-011555 · edgar.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,345 Underlying: Common Stock · 1,669 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F2 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| May 10, 2013 Filed May 14, 2013 22:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 5,852 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-13-008383 · edgar.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,863 Underlying: Common Stock · 5,852 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc. common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc. common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 10, 2013, at the end of the first year of service. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 10, 2013, at the end of the first year of service. Read SEC document |
| May 10, 2013 Filed May 14, 2013 22:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 5,852 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-13-008383 · edgar.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc. common stock. Read SEC document |
| May 08, 2013 Filed May 10, 2013 22:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 2,863 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-13-008229 · edgar.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,715 Underlying: Common Stock · 2,863 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest upon the earlier of May 8, 2014, or the day immediately preceding the next regular annual stockholders meeting. F3 · derivative.expiration_date: 100% of the restricted stock units will vest upon the earlier of May 8, 2014, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 08, 2013 Filed May 10, 2013 22:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (Right to Buy) · Derivative | 8,442 | $0.00 Strike: $52.38 | $0.00 |
DisclosureSEC source: 0001179110-13-008229 · edgar.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,442 Underlying: Common Stock · 8,442 shares Expires 2023-05-08 F1 · derivative.exercise_date: Options vest quarterly over the first year of service upon the earlier of May 8, 2014, or the day immediately preceding the next regular annual stockholders meeting. Read SEC document |
| May 12, 2012 Filed May 16, 2012 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 3,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-12-008473 · edgar.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,926 Underlying: Common Stock · 3,632 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc. common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc. common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 12, 2012, at the end of the first year of service. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 12, 2012, at the end of the first year of service. Read SEC document |
| May 12, 2012 Filed May 16, 2012 00:45 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-12-008473 · edgar.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,811 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc. common stock. Read SEC document |
| May 10, 2012 Filed May 15, 2012 00:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 2,926 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-12-008419 · edgar.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,558 Underlying: Common Stock · 2,926 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 10, 2013, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 10, 2013, at the end of the first year of service. Read SEC document |
| May 10, 2012 Filed May 15, 2012 00:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (Right to Buy) · Derivative | 8,161 | $0.00 Strike: $51.25 | $0.00 |
DisclosureSEC source: 0001179110-12-008419 · edgar.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,161 Underlying: Common Stock · 8,161 shares Expires 2022-05-10 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 10, 2013. Read SEC document |
| July 01, 2011 Filed Jul 6, 2011 22:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 2,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-010709 · edgar.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,741 Underlying: Common Stock · 2,741 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · derivative.exercise_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F2 · derivative.expiration_date: The shares of phantom stock are fully vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| May 12, 2011 Filed May 14, 2011 01:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Stock · Derivative | 66.35 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-11-007987 · edgar.xml · derivative · entry 4 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66.35 Underlying: Common Stock · 66.35 shares Expires not disclosed F5 · derivative.exercise_price: Each share of phantom stock represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F6 · shares: The shares of phantom stock are full vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F5 · price: Each share of phantom stock represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F6 · derivative.exercise_date: The shares of phantom stock are full vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F6 · derivative.expiration_date: The shares of phantom stock are full vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| May 12, 2011 Filed May 14, 2011 01:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 3,632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-11-007987 · edgar.xml · derivative · entry 3 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,632 Underlying: Common Stock · 3,632 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc. common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc. common stock. F4 · derivative.exercise_date: 100% of the restricted stock units will vest on May 12, 2012, at the end of the first year of service. F4 · derivative.expiration_date: 100% of the restricted stock units will vest on May 12, 2012, at the end of the first year of service. Read SEC document |
| May 12, 2011 Filed May 14, 2011 01:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (Right to Buy) · Derivative | 10,141 | $0.00 Strike: $41.29 | $0.00 |
DisclosureSEC source: 0001179110-11-007987 · edgar.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,141 Underlying: Common Stock · 10,141 shares Expires 2021-05-12 F3 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 12, 2012. Read SEC document |
| May 11, 2011 Filed May 14, 2011 01:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 3,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-11-007987 · edgar.xml · derivative · entry 5 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc. common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc. common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on May 11, 2011, at the end of the first year of service. F2 · derivative.expiration_date: 100% of the restricted stock units vested on May 11, 2011, at the end of the first year of service. Read SEC document |
| May 11, 2011 Filed May 14, 2011 01:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,820 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-11-007987 · edgar.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc. common stock. Read SEC document |
| August 06, 2010 Filed Aug 10, 2010 22:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Units · Derivative | 2,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-012454 · edgar.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,359 Underlying: Common Stock · 2,359 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc. common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vested on July 29, 2010, at the end of the first year of service, and were released on August 6, 2010. F2 · derivative.expiration_date: 100% of the restricted stock units vested on July 29, 2010, at the end of the first year of service, and were released on August 6, 2010. Read SEC document |
| August 06, 2010 Filed Aug 10, 2010 22:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-012454 · edgar.xml · nonDerivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2010 Filed Jul 6, 2010 18:21 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Shares · Derivative | 2,782.65 | $0.00 Strike: $34.14 | $0.00 |
DisclosureSEC source: 0001179110-10-011404 · edgar.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,782.65 Underlying: Common Stock · 2,782.65 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one shares of Gilead common stock. F2 · derivative.exercise_date: The shares of phantom stock are full vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F2 · derivative.expiration_date: The shares of phantom stock are full vested and, at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| May 11, 2010 Filed May 13, 2010 23:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 3,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-008591 · edgar.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,820 Underlying: Common Stock · 3,820 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on May 11, 2011, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on May 11, 2011, at the end of the first year of service. Read SEC document |
| May 11, 2010 Filed May 13, 2010 23:43 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 10,860 | $0.00 Strike: $39.26 | $0.00 |
DisclosureSEC source: 0001179110-10-008591 · edgar.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,860 Underlying: Common Stock · 10,860 shares Expires 2020-05-11 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on May 11, 2011. Read SEC document |
| September 01, 2009 Filed Sep 3, 2009 16:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantPhantom Shares · Derivative | 1,747.85 | $45.12 | $78,862.99 |
DisclosureSEC source: 0001179110-09-012848 · edgar.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,747.85 Underlying: Common Stock · 1,747.85 shares Expires not disclosed F1 · derivative.exercise_price: Each share of phantom stock is the economic equivalent of one share of Gilead common stock. F2 · derivative.exercise_date: The shares of phantom stock are fully vested, and at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. F2 · derivative.expiration_date: The shares of phantom stock are fully vested, and at the election of the reporting person, become payable in common stock at a later date identified by the reporting person. Read SEC document |
| July 29, 2009 Filed Jul 31, 2009 21:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Units · Derivative | 2,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-09-011411 · edgar.xml · derivative · entry 2 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,359 Underlying: Common Stock · 2,359 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc. common stock. F3 · derivative.exercise_date: 100% of the restricted stock units will vest on July 29, 2010, at the end of the first year of service. F3 · derivative.expiration_date: 100% of the restricted stock units will vest on July 29, 2010, at the end of the first year of service. Read SEC document |
| July 29, 2009 Filed Jul 31, 2009 21:46 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 6,604 | $0.00 Strike: $49.81 | $0.00 |
DisclosureSEC source: 0001179110-09-011411 · edgar.xml · derivative · entry 1 Lofton Kevin E · CIK 0001468818 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,604 Underlying: Common Stock · 6,604 shares Expires 2019-07-29 F1 · derivative.exercise_date: Options vest quarterly over the first year of service and will be fully vested on July 29, 2010. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.